Category: Latest News
-
BP Makes Largest Oil and Gas Discovery in Brazil in 25 Years
BP (NYSE:BP) announced on Monday a major oil and gas discovery in Brazil’s Santos Basin, marking its largest find in a quarter-century. The discovery lies in the deepwater pre-salt region offshore Brazil, known for its vast hydrocarbon potential. BP plans to increase production to between 2.3 million and 2.5 million barrels of oil equivalent per…
-
Barclays: Retail investor “exuberance” hides caution among institutions
Retail investors have been buying stocks at “full speed,” which is obscuring the more cautious stance seen among institutional investors, according to Barclays analysts. In a recent note, the bank highlighted that retail trading volumes in the U.S. are at historic highs, driven mainly by activity in “unprofitable” tech shares and “crowded shorts.” Data from…
-
US Stock Market Outlook: Caterpillar, Palantir, and Cybersecurity in Focus as August Begins
August kicked off with a thud for Wall Street, as the Nasdaq and S&P 500 posted their worst weekly declines since late May. The Dow Jones Industrial Average fared even worse, notching its steepest weekly drop since early April. For both the Nasdaq and S&P 500, it marked the first time they fell below their…
-
BlackRock Affirms Stablecoins’ Lasting Role in Finance Amid New U.S. Legislation
In a recent note, BlackRock (NYSE:BLK) emphasized that emerging U.S. laws are reinforcing stablecoins’ position within the global financial landscape, while also highlighting bitcoin’s potential as a long-term growth asset. The asset management giant pointed to the recently enacted Genius Act, stating, “New U.S. legislation – notably this month’s Genius Act – is cementing the…
-
New Tariffs, Weak Jobs Data Leads To Sell-Off On Wall Street
Following the downturn seen over the course of Thursday’s session, stocks showed a more substantial move to the downside during trading on Friday. The major averages all moved sharply lower, with the Nasdaq and the S&P 500 (SPI:SP500) pulling back well off Thursday’s record intraday highs. The major averages ended the day off their lows…
-
U.S. Stocks Slide Sharply on Weak Jobs Report; Amazon Disappoints
U.S. equities dropped sharply on Friday following disappointing jobs data and mixed corporate earnings from major tech firms, including Amazon and Apple. Markets also reacted to a fresh wave of tariff announcements from the White House. As of 09:35 ET, the Dow Jones Industrial Average was down 480 points, or 1.1%, the S&P 500 dropped…
-
U.S. Stock Futures Drop Amid New Tariffs, Amazon Miss; Eyes on Jobs Report
U.S. stock futures declined Friday evening as investors weighed the impact of newly announced tariffs from former President Donald Trump, disappointing earnings from Amazon, and awaited key labor market data. As of 05:55 ET, Dow Jones futures were down 375 points (-0.9%), S&P 500 futures lost 55 points (-0.9%), and Nasdaq 100 futures slipped 218…
-
U.S. Stocks Give Back Ground As Early Buying Interest Evaporates
After moving sharply higher early in the session, stocks gave back ground over the course of the trading day on Thursday. The major averages pulled back well off their best levels of the day and into negative territory. The major averages finished the day just off their lows of the session. The Nasdaq edged down…
-
Stock Market Today: S&P 500 Slips After Touching Record Highs Despite Microsoft, Meta Surge
The S&P 500 closed slightly lower Thursday after briefly hitting a new intraday high, as strong earnings from Microsoft and Meta Platforms failed to offset broader market weakness. At 3:08 p.m. ET, the Dow Jones Industrial Average dropped 330 points, or 0.7%. The S&P 500 slipped 0.01% after reaching a record 6,427.02 earlier in the…
-
Lilly shares slide as Mounjaro fails to outperform Trulicity in heart health study
Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment Mounjaro did not demonstrate superiority over Trulicity, its older GLP-1 medication, in a major cardiovascular trial. Following the release of topline findings from the SURPASS-CVOT study, which compared both treatments in adults with type 2 diabetes and…